FY2024 EPS Estimates for Neurogene Increased by Analyst

Neurogene Inc. (NASDAQ:NGNE) – Research analysts at Leerink Partnrs raised their FY2024 earnings estimates for shares of Neurogene in a research note issued to investors on Monday, November 4th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will earn ($4.40) per share for the year, up from their previous estimate of ($4.52). The consensus estimate for Neurogene’s current full-year earnings is ($4.47) per share. Leerink Partnrs also issued estimates for Neurogene’s Q4 2024 earnings at ($1.15) EPS, FY2025 earnings at ($4.55) EPS and FY2026 earnings at ($5.95) EPS.

Separately, HC Wainwright decreased their target price on shares of Neurogene from $51.00 to $49.00 and set a “buy” rating for the company in a research note on Monday, August 12th. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $51.00.

Neurogene Trading Up 8.7 %

Shares of NGNE stock opened at $69.50 on Thursday. Neurogene has a twelve month low of $12.49 and a twelve month high of $73.59. The stock has a 50 day moving average of $44.81 and a 200 day moving average of $39.16.

Neurogene (NASDAQ:NGNE) last posted its quarterly earnings results on Friday, August 9th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.07). The business had revenue of $0.93 million for the quarter.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC acquired a new position in Neurogene in the 1st quarter valued at $120,000. Vanguard Group Inc. raised its position in shares of Neurogene by 906.5% in the first quarter. Vanguard Group Inc. now owns 507,483 shares of the company’s stock valued at $25,831,000 after buying an additional 457,062 shares during the last quarter. Baker BROS. Advisors LP lifted its stake in shares of Neurogene by 0.6% in the first quarter. Baker BROS. Advisors LP now owns 456,015 shares of the company’s stock worth $23,211,000 after buying an additional 2,499 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in Neurogene during the second quarter worth about $1,107,000. Finally, Rhumbline Advisers purchased a new stake in Neurogene during the 2nd quarter valued at about $491,000. Institutional investors and hedge funds own 52.37% of the company’s stock.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.